Boston Scientific Corporation is pushing back the expected approval timeline for its second-generation Acurate neo2 self-expanding transcatheter aortic valve by three years after two trials of the first-generation Acurate neo failed to meet their primary endpoints.
The company originally hoped the results of the SCOPE I and SCOPE II trials of the first generation...